This ability of TRAIL to discriminate between healthy and malignant cells has enabled clinical trials to test soluble recombinant versions of TRAIL and agonistic antibodies [4] in patients affected by different cancers, with promising results for the cytokine in the selective destruction of malignant cells [5,6,7]. The gene discussed is TNFSF10; the disease is cancer.